Goldman Sachs Group, Inc. (The) Analysts Give Roche Holding Ltd. (ROG) a CHF 325 Price Target
Goldman Sachs Group, Inc. (The) set a CHF 325 price objective on Roche Holding Ltd. (VTX:ROG) in a report published on Monday morning. The firm currently has a buy rating on the healthcare company’s stock.
Other research analysts have also issued research reports about the stock. J P Morgan Chase & Co reissued a buy rating on shares of Roche Holding in a research note on Wednesday, June 7th. UBS AG set a CHF 260 price objective on shares of Roche Holding and gave the company a neutral rating in a research note on Thursday, July 6th. Deutsche Bank AG set a CHF 260 price objective on shares of Roche Holding and gave the company a neutral rating in a research note on Friday, July 7th. Societe Generale set a CHF 275 price objective on shares of Roche Holding and gave the company a neutral rating in a research note on Thursday, June 29th. Finally, Morgan Stanley set a CHF 260 price objective on shares of Roche Holding and gave the company a neutral rating in a research note on Wednesday, July 26th. Two research analysts have rated the stock with a sell rating, six have given a hold rating and eight have given a buy rating to the stock. The stock presently has a consensus rating of Hold and an average target price of CHF 267.73.
Shares of Roche Holding (VTX:ROG) opened at 247.70 on Monday. The stock has a 50 day moving average of CHK 244.32 and a 200 day moving average of CHK 251.58. The company has a market cap of CHK 211.35 billion and a price-to-earnings ratio of 21.99. Roche Holding has a 12-month low of CHK 218.30 and a 12-month high of CHK 273.00.
ILLEGAL ACTIVITY NOTICE: This piece of content was published by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are accessing this piece of content on another publication, it was illegally copied and reposted in violation of United States and international copyright laws. The correct version of this piece of content can be read at https://www.thecerbatgem.com/2017/10/06/goldman-sachs-group-inc-the-analysts-give-roche-holding-ltd-rog-a-chf-325-price-target.html.
Roche Holding Company Profile
Roche Holding AG (Roche) is a research-based healthcare company. The Company’s operating businesses are organized into two divisions: Pharmaceuticals and Diagnostics. The Pharmaceuticals Division consists of two business segments: Roche Pharmaceuticals and Chugai. The Diagnostics Division consists of four business areas: Diabetes Care, Molecular Diagnostics, Professional Diagnostics and Tissue Diagnostics.
Receive News & Stock Ratings for Roche Holding Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Roche Holding Ltd. and related stocks with our FREE daily email newsletter.